Bristol-Myers Squibb Company (NYSE:BMY) is among the Best Pharmaceutical Stocks.

On June 2, Bristol-Myers Squibb Company (NYSE:BMY) and SystImmune announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical, reported interim Phase 3 data. It showed that izalontamab brengitecan had statistically significant progress in overall survival and progression-free survival in advanced triple-negative breast cancer and esophageal squamous cell carcinoma. Presenting the results at the 2026 American Society of Clinical Oncology meeting, in TNBC, Iza-bren delivered a median overall survival of 15.9 months as compared to 12.5 months and progression-free survival of 8.5 months versus 3.1 months. It improved the confirmed objective response rate to 51.7% versus 20.5% compared with the physician’s choice of chemotherapy.

Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies

In esophageal cancer, SystImmune said iza-bren posted a median overall survival of 9.8 months compared to 7.2 months and progression-free survival of 4.2 months versus 2.0 months. It raised the objective response rate to 35.3% from 13.1%. The companies said safety remained manageable, with predominantly hematologic adverse events and low interstitial lung disease rates.

Bristol-Myers Squibb Company (NYSE:BMY) is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1